CIK 0001806952
- Non-accelerated filer
- Smaller reporting company
Lyell Immunopharma, Inc.
Sign in to watch- Ticker
- LYEL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833006753
- Phone
- +1 650-695-0677
- Business address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $49,999,983
- in 2 filings
- Open-market sales, last 90 days
- $215,781
- in 9 filings
Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 41 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −165,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +450,000 | 450,000 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −450,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −100,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −85,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +700,000 | 700,000 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −700,000 | 0 | ||
| 2023-09-08 | Klausner Richard Director | Grant or award · Option (right to buy) | +55,000 | 55,000 | ||
| 2023-09-08 | RIEFLIN WILLIAM JL Director | Grant or award · Option (right to buy) | +55,000 | 55,000 | ||
| 2023-09-08 | FRIEDMAN CATHY Director | Grant or award · Option (right to buy) | +55,000 | 55,000 | ||
| 2023-09-08 | NELSEN ROBERT Director | Grant or award · Option (right to buy) | +55,000 | 55,000 | ||
| 2023-09-08 | NABEL ELIZABETH G Director | Grant or award · Option (right to buy) | +55,000 | 55,000 | ||
| 2021-06-21 | GLAXOSMITHKLINE PLC 10% owner | Conversion | +30,253,189 | 30,253,189 | ||
| 2021-06-21 | GLAXOSMITHKLINE PLC 10% owner | Conversion · Series AA Preferred Stock | −30,253,189 | 0 |
Page 8 of 8 · 156 trades